S&P 500   4,288.39 (+0.01%)
DOW   33,433.35 (-0.22%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.97%)
MU   67.96 (-0.10%)
CGC   0.74 (-6.35%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.16 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
S&P 500   4,288.39 (+0.01%)
DOW   33,433.35 (-0.22%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.97%)
MU   67.96 (-0.10%)
CGC   0.74 (-6.35%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.16 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
S&P 500   4,288.39 (+0.01%)
DOW   33,433.35 (-0.22%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.97%)
MU   67.96 (-0.10%)
CGC   0.74 (-6.35%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.16 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
S&P 500   4,288.39 (+0.01%)
DOW   33,433.35 (-0.22%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.97%)
MU   67.96 (-0.10%)
CGC   0.74 (-6.35%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.16 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)

AbCellera Biologics (ABCL) Stock Forecast, Price & News

$4.46
-0.14 (-3.04%)
(As of 10/2/2023 ET)
Compare
Today's Range
$4.43
$4.60
50-Day Range
$4.60
$7.82
52-Week Range
$4.43
$14.97
Volume
2.39 million shs
Average Volume
2.18 million shs
Market Capitalization
$1.29 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.13

AbCellera Biologics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
418.5% Upside
$23.13 Price Target
Short Interest
Bearish
12.80% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.61mentions of AbCellera Biologics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.51) to ($0.63) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.78 out of 5 stars

Medical Sector

767th out of 969 stocks

Pharmaceutical Preparations Industry

370th out of 453 stocks


ABCL stock logo

About AbCellera Biologics (NASDAQ:ABCL) Stock

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company had discovery programs that are either completed, in progress, or under contract with partners. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

ABCL Price History

ABCL Stock News Headlines

Argenx's 28% Surge & Promising Product Propel Investor Confidence (ABCL)
Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
AbCellera's Clinical Carousel: High Risk, Higher Stakes
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
10 Stocks That Could 10X Over the Next 10 Years
Q2 2023 Abcellera Biologics Inc Earnings Call
AbCellera Reports Q2 2023 Business Results
Earnings Preview: AbCellera Biologics
See More Headlines
Receive ABCL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AbCellera Biologics and its competitors with MarketBeat's FREE daily newsletter.

ABCL Company Calendar

Last Earnings
8/03/2023
Today
10/02/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ABCL
Fax
N/A
Employees
590
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$23.13
High Stock Price Forecast
$34.00
Low Stock Price Forecast
$12.00
Forecasted Upside/Downside
+419.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

Net Income
$158.52 million
Pretax Margin
-48.89%

Debt

Sales & Book Value

Annual Sales
$485.42 million
Cash Flow
$0.65 per share
Book Value
$4.31 per share

Miscellaneous

Free Float
195,460,000
Market Cap
$1.29 billion
Optionable
Not Optionable
Beta
0.09
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Carl L.G. Hansen Ph.D. (Age 48)
    CEO, Pres & Chairperson
    Comp: $711.47k
  • Mr. Andrew Booth M.B.A.Mr. Andrew Booth M.B.A. (Age 49)
    Chief Financial Officer
    Comp: $642.42k
  • Dr. Veronique Lecault Ph.D. (Age 38)
    COO & Director
    Comp: $645.07k
  • Mr. Tryn T. Stimart Esq. (Age 53)
    J.D., Chief Legal Officer, Chief Compliance Officer & Corp. Sec.
    Comp: $644.4k
  • Mr. Neil Aubuchon M.B.A. (Age 53)
    Chief Commercial Officer
    Comp: $684.81k
  • Marcie Thiessen CPA
    CGA, Sr. Director of Fin. & Accounting
  • Dr. Ester Falconer Ph.D. (Age 48)
    Chief Technology Officer
  • Josephine Hellschlienger Ph.D.
    Mang. of Investor Relations
  • Ms. Tiffany Chiu B.Sc.
    Ph.D., VP of Communications
  • Alexandra Weirich M.Sc.
    Mang. of Marketing & Communications













ABCL Stock - Frequently Asked Questions

Should I buy or sell AbCellera Biologics stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbCellera Biologics in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ABCL shares.
View ABCL analyst ratings
or view top-rated stocks.

What is AbCellera Biologics' stock price forecast for 2023?

8 analysts have issued 12 month price targets for AbCellera Biologics' stock. Their ABCL share price forecasts range from $12.00 to $34.00. On average, they predict the company's stock price to reach $23.13 in the next year. This suggests a possible upside of 419.7% from the stock's current price.
View analysts price targets for ABCL
or view top-rated stocks among Wall Street analysts.

How have ABCL shares performed in 2023?

AbCellera Biologics' stock was trading at $10.13 at the start of the year. Since then, ABCL shares have decreased by 56.1% and is now trading at $4.45.
View the best growth stocks for 2023 here
.

When is AbCellera Biologics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our ABCL earnings forecast
.

How were AbCellera Biologics' earnings last quarter?

AbCellera Biologics Inc. (NASDAQ:ABCL) issued its quarterly earnings data on Thursday, August, 3rd. The company reported ($0.11) EPS for the quarter, beating analysts' consensus estimates of ($0.13) by $0.02. The company had revenue of $10.10 million for the quarter, compared to analyst estimates of $12.38 million. AbCellera Biologics had a negative net margin of 50.91% and a negative trailing twelve-month return on equity of 6.05%. The company's revenue was down 78.0% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.02) EPS.

What ETFs hold AbCellera Biologics' stock?

ETFs with the largest weight of AbCellera Biologics (NASDAQ:ABCL) stock in their portfolio include ETFMG Treatments Testing and Advancements ETF (GERM).TrueShares Technology, AI & Deep Learning ETF (LRNZ).

When did AbCellera Biologics IPO?

(ABCL) raised $356 million in an initial public offering (IPO) on Friday, December 11th 2020. The company issued 23,000,000 shares at a price of $14.00-$17.00 per share. Credit Suisse, Stifel, Berenberg, SVB Leerink and BMO Capital Markets acted as the underwriters for the IPO.

What is AbCellera Biologics' stock symbol?

AbCellera Biologics trades on the NASDAQ under the ticker symbol "ABCL."

How do I buy shares of AbCellera Biologics?

Shares of ABCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AbCellera Biologics' stock price today?

One share of ABCL stock can currently be purchased for approximately $4.45.

How much money does AbCellera Biologics make?

AbCellera Biologics (NASDAQ:ABCL) has a market capitalization of $1.29 billion and generates $485.42 million in revenue each year. The company earns $158.52 million in net income (profit) each year or ($0.27) on an earnings per share basis.

How many employees does AbCellera Biologics have?

The company employs 590 workers across the globe.

How can I contact AbCellera Biologics?

The official website for the company is www.abcellera.com. The company can be reached via phone at 604-559-9005 or via email at ir@abcellera.com.

This page (NASDAQ:ABCL) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -